Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DMUC5754A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| DMUC5754A | DRUG | Escalating intravenous dose |
Inclusion Criteria: * Life expectancy of at least 12 weeks * Documented willingness to use an effective means of contraception for women of childbearing potential * Measurable disease with at least one lesion that can be accurately measured in at least one dimension Inclusion Criteria Specific to ...
DMUC5754A is an investigational small molecule being studied for the treatment of ovarian cancer and pancreatic cancer. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
DMUC5754A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is currently in Phase 1 clinical development for ovarian cancer and pancreatic cancer.
DMUC5754A is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. One Phase 1 trial has been completed.
DMUC5754A has one completed clinical trial, NCT01335958, which evaluated its safety and pharmacokinetics in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. The trial enrolled 77 participants in the United States.
DMUC5754A is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for ovarian cancer and pancreatic cancer. Its safety and efficacy have not been established.